newsroom.csl

CSL appoints Deborah Waterhouse as CEO & Managing Director

MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and ...
newsroom.csl

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared Melbourne, Australia, and Basel, Switzerland – Oct 5, 2026 – CSL and ...
newsroom.csl

CSL and AWS collaborate to advance biopharmaceutical R&D

KING OF PRUSSIA, Pa., September 29, 2026 | CSL today announced a collaboration with Amazon Web Services (AWS) to apply artificial intelligence and cloud technologies to support the company’s research ...
newsroom.csl

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

The publication follows approval of the trivalent formulation of aQIVc by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom earlier this year for adults aged 50 ...
newsroom.csl

CSL Enters Agreements with the U.S. Government to Lower Drug Prices and Support Investment in U.S. Manufacturing

Agreements support lower prices for CSL therapies and reflect CSL's $1.5 billion plan to expand its U.S. manufacturing capacity in Illinois KING OF PRUSSIA, Pa., - August 31, 2026 – CSL (ASX:CSL; ...
newsroom.csl

European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries

ST. GALLEN, SWITZERLAND – 6 August, 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Commission (EC) has adopted the decision revoking the marketing ...
newsroom.csl

A further update on TAVNEOS® (avacopan) in the European Union

Dear ANCA‑associated vasculitis community, Further to our last update regarding TAVNEOS® (avacopan), we wanted to inform you that the European Commission (EC) has adopted a decision revoking the ...
newsroom.csl

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress ...
newsroom.csl

Our Continued Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Supply and Patient Access

In March, we shared an update regarding HEMGENIX ® (etranacogene dezaparvovec-drlb) availability and our efforts to support people living with hemophilia B while maintaining the highest quality ...
newsroom.csl

An Update on TAVNEOS® (avacopan) in the European Union: Our commitment to continued support for the ANCA Associated Vasculitis Community

Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for ...
newsroom.csl

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...